Browse LCK

Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cell membrane Lipid-anchor Cytoplasmic side Note=Present in lipid rafts in an inactive form.
Domain PF07714 Protein tyrosine kinase
PF00017 SH2 domain
PF00018 SH3 domain
Function

Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK. Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with FYB2 (PubMed:27335501).

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002831 regulation of response to biotic stimulus
GO:0006470 protein dephosphorylation
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006882 cellular zinc ion homeostasis
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0007159 leukocyte cell-cell adhesion
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0009615 response to virus
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0016311 dephosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030168 platelet activation
GO:0030217 T cell differentiation
GO:0030258 lipid modification
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0042110 T cell activation
GO:0042493 response to drug
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045785 positive regulation of cell adhesion
GO:0045862 positive regulation of proteolysis
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046777 protein autophosphorylation
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0046916 cellular transition metal ion homeostasis
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0050688 regulation of defense response to virus
GO:0050690 regulation of defense response to virus by virus
GO:0050792 regulation of viral process
GO:0050817 coagulation
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0050854 regulation of antigen receptor-mediated signaling pathway
GO:0050856 regulation of T cell receptor signaling pathway
GO:0050857 positive regulation of antigen receptor-mediated signaling pathway
GO:0050862 positive regulation of T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051607 defense response to virus
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055069 zinc ion homeostasis
GO:0055074 calcium ion homeostasis
GO:0055076 transition metal ion homeostasis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0071593 lymphocyte aggregation
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097553 calcium ion transmembrane import into cytosol
GO:0098542 defense response to other organism
GO:1902656 calcium ion import into cytosol
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:2000021 regulation of ion homeostasis
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
GO:2001233 regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0001948 glycoprotein binding
GO:0004713 protein tyrosine kinase activity
GO:0004715 non-membrane spanning protein tyrosine kinase activity
GO:0004721 phosphoprotein phosphatase activity
GO:0004722 protein serine/threonine phosphatase activity
GO:0008022 protein C-terminus binding
GO:0016791 phosphatase activity
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0042169 SH2 domain binding
GO:0042578 phosphoric ester hydrolase activity
GO:0042609 CD4 receptor binding
GO:0042610 CD8 receptor binding
GO:0043548 phosphatidylinositol 3-kinase binding
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0051117 ATPase binding
GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component GO:0000242 pericentriolar material
GO:0001772 immunological synapse
GO:0005813 centrosome
GO:0009898 cytoplasmic side of plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0044450 microtubule organizing center part
GO:0045121 membrane raft
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04064 NF-kappa B signaling pathway
hsa04380 Osteoclast differentiation
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-389356: CD28 co-stimulation
R-HSA-389357: CD28 dependent PI3K/Akt signaling
R-HSA-389359: CD28 dependent Vav1 pathway
R-HSA-389513: CTLA4 inhibitory signaling
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-202424: Downstream TCR signaling
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-180292: GAB1 signalosome
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-202433: Generation of second messenger molecules
R-HSA-162906: HIV Infection
R-HSA-109582: Hemostasis
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-451927: Interleukin-2 signaling
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-167590: Nef Mediated CD4 Down-regulation
R-HSA-164944: Nef and signal transduction
R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-389948: PD-1 signaling
R-HSA-210990: PECAM1 interactions
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-1433559: Regulation of KIT signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-202403: TCR signaling
R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis
R-HSA-202430: Translocation of ZAP-70 to Immunological synapse
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LCK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LCK and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29572701melanomaPromote immunity (T function); essential for immunotherapyIn contrast with enhanced activation triggered by pharmacological inhibition, DGKα silencing/genetic deletion led to impaired Lck (lymphocyte-specific protein tyrosine kinase) activation and limited costimulation responses.
23296706colon carcinomaPromote immunityMechanistically, poly-G ODN directly induced the phosphorylation of Lck (an essential element of the T cell-signaling pathway), thereby enhancing the production of IL-2 and CD8 T cell proliferation
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LCK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LCK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1360.819
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2630.847
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0430.969
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5190.288
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8230.559
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1390.939
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.3320.0715
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.0180.0975
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6010.649
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.7630.189
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.240.552
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0840.638
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LCK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LCK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LCK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LCK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LCK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LCK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LCK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLCK
NameLCK proto-oncogene, Src family tyrosine kinase
Aliases lymphocyte-specific protein tyrosine kinase; IMD22; YT16; p56lck; pp58lck; T-lymphocyte specific protein tyr ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LCK collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LCK.
ID Name Drug Type Targets #Targets
DB01254DasatinibSmall MoleculeABL1, ABL2, BCR, BTK, CSK, EPHA2, EPHA5, EPHB4, FGR, FRK, FYN, HSP ......22
DB01830{4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic AcidSmall MoleculeLCK1
DB02010StaurosporineSmall MoleculeCDK2, CHRM1, CSK, GSK3B, ITK, LCK, MAPKAPK2, PDPK1, PIK3CG, PIM1, ......13
DB030231-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-YlamineSmall MoleculeLCK, LYN, SRC3
DB04003{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acidSmall MoleculeLCK1
DB04395Phosphoaminophosphonic Acid-Adenylate EsterSmall MoleculeACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......26
DB069253-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDESmall MoleculeLCK1
DB071462,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINESmall MoleculeLCK1
DB072975,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINESmall MoleculeLCK1
DB08055N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amineSmall MoleculeLCK1
DB08056N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amineSmall MoleculeLCK1
DB08057N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amineSmall MoleculeLCK1
DB08901PonatinibSmall MoleculeABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......15
DB09079NintedanibSmall MoleculeFGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, LCK, LYN, SRC10